U.S. Health Secretary Robert F. Kennedy Jr.'s vaccine advisory committee supported the use of a new antibody shot, clesrovimab, to protect infants against RSV. This follows the successful recommendation of nirsevimab, which showed significant effectiveness in reducing emergency visits for newborns. The committee's decisions greatly influence public health policy and insurance coverage for vaccinations. Amidst discussions on RSV, the panel is also reviewing flu vaccines and the controversial preservative thimerosal, amid ongoing debates regarding vaccine safety from skeptics in the health community.
The Advisory Committee on Immunization Practices voted 5-2 to endorse the use of Merck's clesrovimab to protect infants against RSV, reflecting a significant advancement in infant health.
The committee's recommendations influence how vaccinations are covered by insurance and are crucial in shaping public health policies regarding immunization.
Collection
[
|
...
]